The Problem

The client R&D team was in a race to launch a new immunotherapy within a new indication, which over-indexed in ethnic populations. They didn’t see the volume of patients in this disease state and recruiting was languishing for their Phase 2 trial. 

The Solution

CHM recognized that these patients were more apt to be treated by their community oncologist and would not be open to transitioning their care to an academic institution. Our team crafted a refined community-based trial recruitment strategy.

The Results

Client doubled enrollment fulfilling trial enrollment within 8 months and ahead of schedule.